Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade

As we look forward to the bright future of immune checkpoint blockade (ICB) therapy, there is still lacking a pharmacokinetic marker to understand the inter-individual differences in ICB response. ICB therapy is based on IgG antibodies that share the same homeostatic pathway with serum albumin. Ther...

Full description

Saved in:
Bibliographic Details
Main Author: Ming Zheng
Format: Article
Language:English
Published: BMJ Publishing Group 2022-12-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/12/e005670.full
Tags: Add Tag
No Tags, Be the first to tag this record!